Canadian public policies and practices related to drug prices, utilization and expenditures

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 12, Issue 1, 2003, Pages 23-54

  Sketris, Ingrid ^a   Bowles, Susan ^b   Manuel, Richard ^b  

^a Nova Scotia Hlth Res Foundation   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Copayment; Drug utilization; Pharmaceutical policy

Indexed keywords

GENERIC DRUG;

CANADA; DRUG COST; DRUG FORMULARY; DRUG MARKETING; DRUG UTILIZATION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; PATENT; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

EID: 4644289450     PISSN: 15385698     EISSN: None     Source Type: Journal    
DOI: 10.1300/J371v12n01_02     Document Type: Review

References (131)

1. Anon. Academic Reference Manual 2000; Canadian Health Care Information for Pharmacy and Medical students. 4th Edition. Montreal; IMS Health: 2000.
2. Anderson GM, Lexchin J. Strategies for improving prescribing practice. CMAJ 1996a; 154(7):1013-7.
3. Anderson G, Kerluke K. Distribution of prescription drug exposures in the elderly: Description and implications. J Clin Epidemiol 1996b;49(8):929-35.
4. Anderson GM, Kerluke KJ, Pulcins IR, Hertzman C, Barer ML. Trends and determinants of prescription drug expenditures in the elderly: Data from the British Columbia Pharmacare Program. Inquiry 1993;30(2):199-207.
5. Anderson GM, Spitzer WO, Weinstein MC, Wang E, Blackburn JL, Bergman U. Benefits, risks, and costs of prescription drugs: A scientific basis for evaluating policy options. Clin Pharmacol Ther 1990;48(2):111-9.
6. Angus DE, Karpetz HM. Pharmaceutical policies in Canada. Pharmacoeconomics 1998; 14: (Suppl 1): 81-96.
7. Anis AH. Substitution law, insurance coverage, and generic drug use. Medical Care 1994;32(3):240-56.
8. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics 2000;18(1):55-62.
9. Anis AH, Rahman T, Schechter MT. Using pharmacoeconomic analysis to make drug insurance coverage decisions. Pharmacoeconomics 1998;13(1 Pt 2):119-26.
10. Anis AH, Carruthers G, Carter A et al. Variability in prescription drug utilization: Issues for research. Can Med Assoc J 1996;154(5):635-40.
11. Applied Management, Fraser Group, Tristat Resources. Canadians' Access to Insurance for prescription Medicines. Health Transition Fund Project NA202, Health Canada March 2000.
12. ASHP guidelines on formulary system management. Am J Hosp Pharm 1992;49: 648-652.
13. Audet AM, Greenfield S, Field M. Medical practice guidelines: Current activities and future directions. Ann Intern Med 1990;30:709-714.
14. Bacovsky RA. Federal, provincial and territorial government-sponsored drug plans and drug databases. Background information prepared for the conference on National Approaches to Pharmacare. Integra Consulting, Alberta, 1997.
15. Baladi J-F, Menon D, Otten N. Use of economic evaluation guidelines: 2 years experience in Canada. Health Economics 1998; 7:221-227.
16. Birch S. Relationship between increasing prescription charges and consumption in groups not exempt from charges. J R Coll Gen Practit 1986;36:154-156.
17. Blustein J. Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Aff 2000:19:219-229.
18. Boulet AP, Tessier G. Reference-based pricing in British Columbia: Implications for cardiologists - an analysis. Can J Cardiol 1997;13(1):46-51.
19. Bourgault C, Elstein E, Le Lorier J, Suissa S. Reference-based pricing of prescription drugs: Exploring the equivalence of angiotensin-converting-enzyme inhibitors. Can Med Assoc J 1999;161:255-260.
20. Brown G. Do institutional formulary systems conflict with provision of pharmaceutical care. Can J Hosp Pharm 2000; 53(1):113-4.
21. Brown M, Murray TJ, Sketris I, Fisk J, LeBlanc JC, Schwartz CE, Skedgel C. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: First estimates, Int J Technol Asess Health Care 2000;16(2):[accepted].
22. Brunt JH, Chappell NL, Maclure M, Cassels A. Assessing the effectiveness of government and industry media campaigns on seniors perceptions of reference-based pricing policy. J Appl Gerontol 1998;276-295.
23. Burge F, Kephart G, Flowerdew G, Putnam W, Comeau D, Whelan AM, Sketris I, Sclar DA. Physician characteristics in relation to cardiovascular drugs commonly prescribed for hypertension in Nova Scotia. Can J Clin Pharmacol 2001;8(3):139-145.
24. Busser JR. Inappropriate practices in prescribing: who decides and how? [letter; comment]. CMAJ 1997;156(12):1695-6.
25. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PAC, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. J Am Med Assoc 1999;282:1458-1465.
26. Canadian Cardiovascular Society. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Can J Cardiol 1997;13:33-45.
27. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada 2nd Edition November 1997.
28. Canadian Institute for Health Information. [online] Last updated December 11, 2000 [cited January 22, 2001] [16 screens]. Available from: http://www.cihi.ca/medrls/11dec2000execsumm.shtml.
29. Canadian Pharmacists Association: Building Pharmacare: Expanding the Health Care Contract with Canadians. Discussion Paper. An integrated approach prosed by the Canadian Pharmacy Coalition on Pharmacare. Canadian Pharmacists Association. Ottawa, November 1999.
30. Carlson JA. Antimicrobial formulary management: meeting the challenge in a health maintenance organization. Pharmacotherapy 1991;11(1-Pt2):32S-35S.
31. Chassin MR. Practice guidelines: Best hope for quality improvement in the 1990s. J Occup Med 1990;32:1199-1206.
32. Chiles V. Drug claim cost: A Green Shield Canada study. Can Pharm J 1995128(9): 37-43.
33. Cox JL, on behalf of the ICONS investigators. Optimizing disease management at a health care system level: The rationale and methods of the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. Can J Cardiol 1999;15(7):787-96.
34. Crane VS. How to use structured decision making in developing therapeutic, cost-effective formulary systems. Hospital Formulary 1993;28:859-862, 865-867.
35. Drugs Directorate, Health Canada. PAAB and Drugs Directorate Roles and Consultation Related to Advertising Review. [online January 11, 1996-cited April 30, 2001] Available at http://www.hc-sc.gc.ca/hpb-dgps/therape...s/english/ policy/issued/paapb-adv_e.html.
36. D'Sa MM, Hill DS, Stratton TP. Diffusion of innovation I: Formulary acceptance rates of new drugs in teaching and non-teaching British Columbia hospitals - a hospital pharmacy perspective. Can J Hosp Pharm 1994;47(6):254-60.
37. D'Sa MM, Hill DS, Stratton TP. Diffusion of innovation II: Formulary acceptance rates of new drugs in teaching and non-teaching British Columbia hospitals - a drug development perspective. Can J Hosp Pharm 1995;48(1):7-15.
38. Eastman HC. Pharmaceutical price review in Canada. Pharmacoeconomics 1994; 5: 278-285.
39. Fassbender K, Pickard S. A policy impact analysis of pharmaceutical cost containment strategies in Alberta. Institute of Health Economics. Working paper 00-12. August, 2000.
40. Freund DA, Willison D, Reeher G, Cosby J, Ferraro A, O'Brien B. Outpatient pharmaceuticals and the elderly: Policies in seven nations. Health Aff 2000;19: 259-266.
41. Ghent N. $2.7 million tab for limited use scrips. Pharmacy Post 2001;9(4):11.
42. Gill JN, Frighetto L, Marra C, Jewesson P. Patients' perceptions about substitution of a reference drug while in hospital: Focus on H2-receptor antagonists. Can J Hosp Pharm 2000a; 53(2):86-91.
43. Gill NJ, Frighetto L, Marra C, Jewesson P. Influence of the British Columbia reference drug program on hospital formularies: A survey of hospital pharmacy managers. Can J Clin Pharmacol 2000b;7(2):109-14.
44. Glennie JL, Torrance GW, Baladi JF et al. The revised Canadian guidelines for the economics evaluation of pharmaceuticals. Pharmacoeconomics 1999; 15(5):459-68.
45. Godwin M, Chapman J, Mowat D, Racz W, McBride J, Tang J. Delisting of drugs in Ontario. How attitudes and prescribing strategies of family physicians in the Kingston area changed. Can Med Assoc J 1996;42:1309-1316.
46. Grabowksi H, Mullins D. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997;45:535-544.
47. Grootendorst PV, Dolovich L Holbrook AM, Levy A, O'Brien BJ. The impact of reference-based pricing of ACE inhibitors and calcium channel blockers on the issue of prescription drugs, hospital and physicians' services in British Columbia Health Transition Fund (Project NA222) 1999.
48. Harris BL, Stergachis A, Reid LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a Health Maintenance Organization. Med Care 1990; 28:907-917.
49. Hayward RSA. Clinical practice guidelines on trial. Can Med Assoc J 1997;156: 1725-1727.
50. Holbrook AM, McLeod SM, Fisher P, Levine MA. Developing a Canadian Prescribing Practices Network. CMAJ 1996;154(9):1325-31.
51. Holbrook A, O'Brien B, Grootendorst P. Reference-based pricing (RBP) of prescription drugs [letter; comment]. Can J Cardiol 1997;13(7):689-90.
52. Hurley J, Johnson NA. The effects of co-payments within drug reimbursement programs. Can Pub Policy 1991;17:473-485.
53. Huttin C. The use of prescription charges. Health Policy 1994;27:53-73.
54. Hux J, Fielding DA. The Ontario Drug Benefit Program Copayment: Its Impact on Access for Ontario Seniors and Charges to the Program. A Background Document. Institute for Clinical Evaluative Sciences. April 24, 1997.
55. Hux J, Naylor CD. Drug prices and third party payment. Do they influence drug selection? Pharmacoeconomics 1994;5:343-350.
56. Hux JE, Melady MP, DeABoer D. Confidential prescriber feedback and education to improve antibiotic use in primary care: A controlled trial. CMAJ 1999; 161(4): 388-92.
57. Jacobs P, Bachynsky J. Public policies related to drug formularies in Canada: Economic issues. Working Paper 00-2. Institute for Health Economics. University of Alberta. Edmonton, Alberta 2000. ISSN 1481-3823.
58. Jewesson PJ. The hospital drug formulary system: Just a leftover? Opinions of a tired but still committed formulary system manager. Can J Hosp Pharm 2000;53(3):179-81.
59. Kalant N. Re: AP Boulet, G Tessier. Reference-based pricing in British Columbia: Implications for cardiologists-an analysis. 1997;13:46-51 [letter; comment]. Can J Cardiol 1997; 13(7):640, 689.
60. Kalant N. Re: AP Boulet, G Tessier. Reference-based pricing in British Columbia: Implications for cardiologists-an analysis. 1997;13:46-51 [letter; comment]. Can J Cardiol 1997; 13(7):640, 689.
61. Kanouse DE, Winkler JD, Kosecoff J et al. Changing medical practice through technology assessment: An evaluation of the NIH consensus development program. Santa Monica, Calif: RAND; 1989.
62. Kent H. BC's reference-based pricing stirs controversy [news]. CMAJ 2000;162(8): 1190.
63. Kephart G, Skedgel C, Sketris I et al. The effect of user fees on the consumption of H2 blockers in the Nova Scotia Senior's Pharmacare program. Can J Clin Pharmacol 2001(8):23.
64. Kephart G, Sketris I, Maclean D, Kass K, Nagpal S. Management of high blood cholesterol levels in Nova Scotia adults: Comparison with the NCEP II and European clinical practice guidelines. Am J Manag Care 2000 Sep; 6(9):1017-28.
65. Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost sharing. Soc Sci Med 1985;10:1063-1069.
66. Levy R. Prescription cost sharing: Economic and health impacts. Implications for health policy. Pharmaceconomics 1992;2:219-237.
67. Lexchin J. Canadian Marketing Codes: How well are they controlling pharmaceutical promotion? Int J Health Serv 1994;24(1):91-104.
68. Lexchin J. Pharmaceuticals, Patents, and Politics. Int J Health Serv 1993;23(1): 147-60.
69. Lexchin J. Prescribing by Canadian general practitioners: Review of the English Language literature. Can Fam Physician 1990;36: 465-70.
70. Lexchin J. Income class and pharmaceutical expenditures in Canada: 1964-1990. Can J Public Health 1996;87(1):46-50.
71. Lexchin J. Enforcement of codes governing pharmaceutical promotion: What happens when companies breach advertising guidelines? Can Med Assoc J 1997; 156(3): 351-6.
72. Lindsey R, West DS. National Pharmacare, reference-based pricing, and drug R&D: A critique of the National Forum on Health's recommendations for pharmaceutical policy. Can Public Policy 1999;25:1-27.
73. Loh EA, Gosnell T, Poston J. Evaluation of pharmacy resources required when submitting prescription claims to drug plans. Canadian Pharmacists Association, Dec 1997.
74. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989;321:1306-1311.
75. Lundberg L, Johannesson M, Isacson DGL, Borguist L. Effects of user charges on the use of prescription medicines in different socio-economic groups. Health Policy 1998;44:123-134.
76. Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socio-economic assessments and drug adoption decisions. Soc Sci Med 1997;45:511-521.
77. MacCara ME, Sketris IS, Comeau DG, Weerasinghe SD. Impact of a limited fluoroquinolone reimbursement policy on antimicrobial prescription claims. Ann Pharmacother 2001; 35:852-858.
78. MacKinnon NJ. Drug Use Management: Prescribing Solutions. Health Policy Forum 2000 (Winter): 19-22.
79. MacKinnon NJ. When it comes to formularies, where is our focus? (editorial). Can J Hosp Pharm 1999;52(3):143-4.
80. MacKinnon NJ, Kumar R. Prior Authorization Programs: A Critical Review of the Literature. Journal of Managed Care Pharmacy 2001;7(4):297-302.
81. MacLeod S. A paper highlighting discussion from a forum on: Optimal Drug Therapy. Toronto, ON: 1999.
82. Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R, Whiteside C, Wright JM. Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet 1998;352(9132):943-8.
83. McGregor M. Coverage of drug costs: Reference-based pricing. Can J Cardiol 1998; 14(5):666-8.
84. Melfi CA, Drake BG, Tierney WM. The role of public opinion in drug resource allocation decisions. Pharmacoeconomics 1996;9:106-112.
85. Menon D, Schubert F, Torrance G. Canada's new guidelines for the economic evaluation of pharmaceuticals. Medical Care 1996; 34(12):DS77-DS86.
86. Metge C, Black C, Peterson S, Kozyrskyj AL. The population's use of pharmaceuticals. Med Care 1999;37(Suppl 6):JS42-JS59.
87. Miller E, Blatman B, Einarson TR. A survey of population-based drug databases in Canada. CMAJ June 1996;154(12):1855-64.
88. Moore WJ, Gutermuth K, Pracht EE. Systemwide effects of Medicaid retrospective drug utilization review programs. J Health Polit Policy Law 2000;25:653-688.
89. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Trends in oral antihyperglycemic and insulin use in the Nova Scotia Senior Population (1993-1999). Can J Clin Pharmacol 2002;9(3):123-129.
90. Mullens A. Reference-based pricing: Will other provinces follow the BC lead? CMAJ 1998;158(2):239-41.
91. Narine L, Senathirajah M, Smith T. Evaluating reference-based pricing: Initial findings and prospects. Can Med Assoc J 1999;161:286-288.
92. National Forum on Health. Canada Health Action: Building on the Legacy, Volume 1. The Final Report. Ottawa. Health Canada: 1997. Available online: http://www.nfh.hc-sc.ca/publicat/finalvol1.
93. National Forum on Health. Canada Health Action: Building on the Legacy, Volume 2. Synthesis Reports and Issues Papers. Ottawa: Health Canada: 1997. Available online: http://www.nfh.hc-sc.ca/publicat/finalvol2.
94. National Health Expenditures in Canada 1975-1994. Ottawa: Policy and Consultation Branch, January 1996.
95. Naylor CD. Health care in Canada: Incrementalism under fiscal duress. Health Affairs 1999;18:9-26.
96. O'Brien B. The effect of patient charges on the utilization of prescription medicines. J Health Econ 1989;8:109-132.
97. Patented Medicines Price Review Board (PMPRB). Eighth Annual Report for the Year Ended December 31, 1995. Ottawa: PMPRB, 1996.
98. Patented Medicines Price Review Board. A Comparison of Pharmaceutical Research and Development Spending in Canada and Selected Countries-S4709, Ottawa, Ont., 1997.
99. Patented Medicines Price Review Board. 1999 Annual Report (online) [13 screens]. January 2000 [cited October 30, 2000]. Available from: http://www.pmprb_cepmb.gc.ca/ar-99e.htm.
100. Poston J, Kennedy R, Waruszynski B. Initial results from the Community Pharmacist Intervention Study. Can Pharm J 1995;Dec/Jan: 18-25.
101. Quinn CE, Barisan A. Understanding, creating, and working with formulary systems. Am J Man Care 1999;5:1311-1317.
102. Reeder CE, Lingle EW, Schulz RM et al. Economic impact of cost-containment strategies in third party programmes in the US (Part 1). Pharmacoeconomics 1993;4:92-103.
103. Rees S. Lopatka H. Initial experience from an on-line trial prescription program. Can J Clin Pharmacol 2001 (8): 32 (Abstract).
104. Rigter H. Recent public policies in the Netherlands to control pharmaceutical pricing and reimbursement. Pharmacoeconomics 1994;6 (Suppl 1):1-21.
105. Rojas-Fernandez CH, Kephart GC, Sketris IS, Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heard disease or stroke: Data from the 1995 population-based Nova Scotia Health Survey. Can J Cardiol 1999; 15(3):291-6.
106. Rubin RJ, Mendelson DN. A framework for cost-sharing policy analysis. Pharmacoeconomics 1996;10:56-67.
107. Ryan M, Birch S. Charging for health care: Evidence on the utilization of NHS prescribed drugs. Soc Sci Med 1991;33:681-687.
108. Shulman SR. The Canadian Patented Medicine Prices Review Board: New rules and new status. Pharmacoeconomics 1994;6(suppl 1):71-79.
109. Silversides A. "Academic detailing" improving prescribing practices in North Vancouver, conference told. CMAJ 1997;156(6):876-8.
110. Sketris I, Brown M, Murray J, Fisk JD, McLean K. Drug therapy in multiple sclerosis: A study of Nova Scotia senior citizens. Clin Therap 1996;18(2):303-18.
111. Sketris I, Hill S. The Australian national publicly subsidized Pharmaceutical Benefits Scheme: Any lessons for Canada? Can J Clin Pharmacol 1998;5(2):111-8.
112. Sketris I, King P, Frail D, Kephart G, Hoar J, Coleman C. Evaluation of a trial prescription program in NS. Pharmacotherapy 1999a;19(4):496 (Abstract).
113. Sketris I, McLean-Veysey P, on behalf of the Drug Evaluation Alliance of Nova Scotia (DEANS). A provincial program in Nova Scotia to decrease the use of wet nebulization respiratory medications. J Manag Care Pharm 2000;6(6):457-61.
114. Sketris IS, Nagpal S, O'Brien B, Kephart GC, Wheeler-Usher D, Grace E. Proton pump inhibitor use under the Nova Scotia Pharmacare's Exception Drug Program. Can J Clin Pharmacol 1999b;6(1):50.
115. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Soc Sci Med 1997;45:523-533.
116. Smith DM, McKercher PL. The elimination of selected drug products from the Michigan Medicaid formulary: A case study. Hosp Form 1984;19:366.
117. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. New Engl J Med 1987;317:550-556.
118. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: Research in need of discipline. Milbank Q 1993;71:217-252.
119. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admissions to hospitals and nursing homes. New Engl J Med 1991;325-1072-1077.
120. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New Engl J Med 1994;331:650-655.
121. Stoddart GL, Barer ML, Evans RC, Bhatia V. Why not user charges? The real issues. A discussion paper. The Premier's Council on Health, Well-Being and Social Justice. Ontario. September, 1993.
122. Stuart B, Zacker C. Who bears the burden of Medicaid drug co-payment policies? Health Aff 1999;18:201-212.
123. Tamblyn RM, McLeod PJ, Abrahamowicz M et al. Questionable prescribing for elderly patients in Quebec. CMAJ 1994; 150: 1801-1809.
124. Tamblyn R, Laprise R, Hanley JA, Abahamowicz M, Scott S, Mayo N et al. Adverse events associated with prescription drug cost sharing among poor and elderly persons. J Am Med Assoc 2001;285:421-429.
125. Thatcher C. Zoloft's patent problems. Canadian Pharmaceutical Journal 2001;(2):12.
126. Titlow K, Randel L, Clancy CM, Emanuel EJ. Drug coverage decisions: The role of dollars and values. Health Aff 2000;19:240-247.
127. United States International Trade Commission. Pricing of prescription drugs. Washington: United States International Trade Commission; 2003.
128. Vandergrift M, Kanavos P. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 1997:41(3):241-60.
129. Walser BL, Ross-Degnan D, Soumerai SB. Do open formularies increase access to clinically useful drugs? Health Aff 1996;15:95-109.
130. Wolf HK, Andreou P, Bata IR, Comeau DG, Gregor RD, Kephart GC, MacLean DR, Sketris IS. Trends in the prevalence and treatment of hypertension in Halifax County from 1985 to 1995. Can Med Assoc J 1999;161(6):599-704.
131. Woolf SH. Practice guidelines: A new reality in medicine. III: Impact on patient care. Arch Intern Med 1993;153:2646-2655.